Beigene (NASDAQ:ONC) Stock Price Down 5.4% - Should You Sell?

Shares of Beigene, Ltd. (NASDAQ:ONC - Get Free Report) fell 5.4% during trading on Tuesday . The stock traded as low as $249.52 and last traded at $250.13. 83,899 shares were traded during trading, a decline of 81% from the average session volume of 446,589 shares. The stock had previously closed at $264.42.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on ONC shares. Royal Bank of Canada dropped their target price on Beigene from $312.00 to $311.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. JPMorgan Chase & Co. upped their price objective on shares of Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, April 21st. Guggenheim upped their price target on Beigene from $348.00 to $350.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Sanford C. Bernstein set a $259.00 target price on Beigene in a report on Thursday, March 13th. Finally, Bank of America upgraded shares of Beigene from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Beigene currently has an average rating of "Buy" and an average price target of $319.00.

Beigene Stock Down 3.9%

The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average of $242.48. The stock has a market capitalization of $27.81 billion, a P/E ratio of -30.83, a P/E/G ratio of 7.73 and a beta of 0.30.

Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.12 billion. On average, research analysts predict that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Insider Transactions at Beigene

In other Beigene news, insider Titus B. Ball sold 134 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $258.36, for a total transaction of $34,620.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Chan Henry Lee sold 700 shares of Beigene stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $256.11, for a total value of $179,277.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 186,498 shares of company stock valued at $47,406,066. Corporate insiders own 6.62% of the company's stock.

Beigene Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.